Imvotamab

DB17331InvestigationalProtein Based Therapies

Imvotamab: Overview.

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3 epsilon chain, and T-cell surface glycoprotein CD3
Curator reviewed

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Imvotamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.